Logo

Ocugen and Bharat Biotech Present Results of Covaxin in P-III Study Against COVID-19

Share this

Ocugen and Bharat Biotech Present Results of Covaxin in P-III Study Against COVID-19

Shots:

  • The P-III study involves assessing Covaxin (COVID-19 vaccine candidate) vs PBO in 25-798 patients aged 18-98 yrs include 2-750 >60 yrs. of age & 7-065 with comorbidities in over 25 centers across India and is being conducted in partnership with ICMR & NIV
  • The results from the P-III study demonstrates overall efficacy of 77.8% with 93.4% protective against severe COVID-19 alone while efficacy data demonstrates 65.2% protection against B.1.617.2 (delta) & B.1.351 (beta) variant
  • The company will submit BLA for Covaxin in the US & initiates the discussions with Health Canada for regulatory approval while Covaxin is currently being administered under EUA in 13 countries

  | Ref: Globe Newswire | Image: Crunchbase

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions